冠脉无复流现象治疗的研究进展

李秋艳; 苏强

doi:10.16766/j.cnki.issn.1674-4152.002868

冠脉无复流现象治疗的研究进展

doi: 10.16766/j.cnki.issn.1674-4152.002868

李秋艳,
苏强^,

桂林医学院附属医院心血管内科，广西桂林 541000

基金项目:

2020年广西重点研发计划项目桂科AB20159005

详细信息

通讯作者:
苏强，E-mail：suqiang1983@glmc.edu.cn

中图分类号: R542.22
计量
- 文章访问数: 211
- HTML全文浏览量: 24
- PDF下载量: 25
- 被引次数: 0
出版历程
- 收稿日期: 2022-04-06

Research progress in the treatment of coronary no-reflow phenomenon

LI Qiu-yan,
SU Qiang^,

Department of Cardiology, the Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541000, China

摘要

摘要: 心血管疾病是人群中常见的死亡原因之一，随着人口老龄化的加速，心血管疾病中以急性心肌梗死为代表的急性冠脉综合征(ACS)的发病率逐年上升。一旦发生ACS，尽早恢复冠脉的血流就尤为重要，而急诊经皮冠状动脉介入治疗(PCI)仍是目前首选的治疗方案。无复流现象是PCI术后常见的并发症，它是指在冠脉介入治疗过程中，心外膜冠脉狭窄或闭塞已得到正常开通，但由于微循环水平血液仍不能完全恢复，使缺血心肌组织未得到有效再灌注的现象。当冠脉产生无复流现象时，使得再灌注治疗的有益效果减弱，主要不良心脏事件(MACEs)的发生率明显增加，导致患者的不良预后。目前冠脉无复流现象的病理生理学机制尚不完全清楚，可能与冠状动脉微循环障碍有关，分子机制包括炎症通路的激活、缺血与再灌注所致内皮细胞损伤、血栓栓塞症有关的损伤、微血管痉挛、白细胞浸润和细胞水肿等。由于无复流现象与不良的临床结果密切相关，因此，有效的预防和治疗策略非常重要。近来的研究表明，术前预防应用他汀类、抗血小板类、血管扩张剂及某些抗炎药物有助于减少无复流现象的发生、重建冠状动脉血流并改善患者的预后。此外，介入器械的预防使用也具有一定的应用前景。本文就近几年防治冠脉无复流现象治疗的研究进展进行综述。
- 无复流 /
- 经皮冠状动脉介入治疗 /
- 急性心肌梗死
Abstract: Cardiovascular disease is a common cause of death worldwide. With the acceleration of population aging, the incidence of acute coronary syndrome (ACS), represented by acute myocardial infarction, is increasing every year. When ACS occurs, coronary blood flow must be restored as soon as possible, and emergency percutaneous coronary intervention (PCI) remains the preferred treatment option. No-reflow phenomenon is a common complication after PCI, it refers to the normal opening of epicardial coronary stenosis or occlusion during coronary intervention, but the blood myocardial tissue has not been effectively re-perfused because the blood at the microcirculation level cannot be completely recovered. When coronary no-reflow phenomenon occurs, the beneficial effect of reperfusion therapy is weakened, and the incidence of major adverse cardiac events (MACES) is significantly increased, resulting in poor patient prognosis. At present, the pathophysiological mechanism of coronary no-reflow phenomenon is not fully understood, and it may be related to coronary microcirculation disorders. Molecular mechanisms include the activation of inflammatory pathways, endothelial cell damage caused by ischaemia and reperfusion, thromboembolism-related damage, microvascular spasm, leukocyte infiltration and cell oedema. No-reflow phenomenon is closely associated with poor clinical outcomes, thus, effective prevention and treatment strategies are important. Recent studies have shown that the preoperative prophylactic use of statins, antiplatelets, vasodilators and certain anti-inflammatory drugs can reduce the occurrence of no-reflow, restore coronary blood flow and improve patient outcomes. In addition, the preventive use of interventional devices has certain application potential. This article reviews the research progress in the prevention and treatment of coronary no-reflow phenomenon in recent years.
- No-reflow /
- Percutaneous coronary intervention /
- Acute myocardial infarction
利益冲突 无

HTML全文

参考文献(45)

[1]	REZKALLA S H, STANKOWSKI R V, HANNA J, et al. Management of no-reflow phenomenon in the catheterization laboratory[J]. JACC Cardiovasc Interv, 2017, 10(3): 215-223. doi: 10.1016/j.jcin.2016.11.059
[2]	KLEINBONGARD P, HEUSCH G. A fresh look at coronary microembolization[J]. Nat Rev Cardiol, 2022, 19(4): 265-280. ALLENCHERRIL J, JNEID H, ATAR D, et al. Pathophysiology, diagnosis, and management of the no-reflow phenomenon[J]. Cardiovasc Drugs Ther, 2019, 33(5): 589-597. doi: 10.1038/s41569-021-00632-2
[3]	ALLENCHERRIL J, JNEID H, ATAR D, et al. Pathophysiology, diagnosis, and management of the no-reflow phenomenon[J]. Cardiovasc Drugs Ther, 2019, 33(5): 589-597.
[4]	GIBSON C M, CANNON C P, DALEY W L, et al. TIMI frame count: A quantitative method of assessing coronary artery flow[J]. Circulation, 1996, 93(5): 879-888. doi: 10.1161/01.CIR.93.5.879
[5]	CENKO E, RICCI B, KEDEV S, et al. The no-reflow phenomenon in the young and in the elderly[J]. Int J Cardiol, 2016, 222: 1122-1128. doi: 10.1016/j.ijcard.2016.07.209
[6]	TURSCHNER O, D' HOOGE J, DOMMKE C, et al. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury[J]. Eur Heart J, 2004, 25(9): 794-803. doi: 10.1016/j.ehj.2004.01.006
[7]	TAMBE A A, DEMANY M A, ZIMMERMAN H A, et al. Angina pectoris and slow flow velocity of dye in coronary arteries: a new angiographic finding[J]. Am Heart J, 1972, 84(1): 66-71. doi: 10.1016/0002-8703(72)90307-9
[8]	NERI M, RIEZZO I, PASCALE N, et al. Ischemia / reperfusion injury following acute myocardial infarction: a critical issue for clinicians and forensic pathologists[J]. Mediators Inflamm, 2017, 2017: 7018393. DOI: 10.1155/2017/7018393.
[9]	LI S, CHEN J, LIU M, et al. Protective effect of HINT2 on mitochondrial function via repressing MCU complex activation attenuates cardiac microvascular ischemia-reperfusion injury[J]. Basic Res Cardiol, 2021, 116(1): 65. doi: 10.1007/s00395-021-00905-4
[10]	ZHANG H, KIM H, PARK B W, et al. CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia-reperfusion injury[J]. Exp Mol Med, 2022, 54(1): 23-34. doi: 10.1038/s12276-021-00720-w
[11]	SABER R S, EDWARDS W D, BAILEY K R, et al. Coronary embolization after balloon angioplasty or thrombolytic therapy: an autopsy study of 32 cases[J]. J Am Coll Cardiol, 1993, 22(5): 1283-1288. doi: 10.1016/0735-1097(93)90531-5
[12]	MUTLUER F O, URAL D, GVNGÖR B, et al. Association of interleukin-1 Gene cluster polymorphisms with coronary slow flow phenomenon[J]. Anatol J Cardiol, 2018, 19(1): 34-41.
[13]	LI Q, ZHAO Y G, WANG Z, et al. Effects of first high-dose atorvastatin loading in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention[J]. Am J Ther, 2018, 25(3): e291-e298. doi: 10.1097/MJT.0000000000000370
[14]	GARCÍA-MÉNDEZ R C, ALMEIDA-GUTIERREZ E, SERRANO-CUEVAS L, et al. Reduction of no reflow with a loading dose of atorvastatin before primary angioplasty in patients with acute st myocardial infarction[J]. Arch Med Res, 2018, 49(8): 620-629. doi: 10.1016/j.arcmed.2018.10.006
[15]	VALGIMIGLI M, BUENO H, BYRNE R A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J, 2018, 39(3): 213-260. doi: 10.1093/eurheartj/ehx419
[16]	KAMRAN H, JNEID H, KAYANI W T, et al. Oral antiplatelet therapy after acute coronary syndrome: a review[J]. Jama, 2021, 325(15): 1545-1555. doi: 10.1001/jama.2021.0716
[17]	COHEN M V, DOWNEY J M. What are optimal P2Y12 inhibitor and schedule of administration in patients with acute coronary syndrome?[J]. J Cardiovasc Pharmacol Ther, 2020, 25(2): 121-130. doi: 10.1177/1074248419882923
[18]	HE Z, DAVIDSON S M, YELLON D M. The importance of clinically relevant background therapy in cardioprotective studies[J]. Basic research in cardiology, 2020, 115(6): 69. doi: 10.1007/s00395-020-00830-y
[19]	SCHVPKE S, NEUMANN F J, MENICHELLI M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes[J]. N Engl J Med, 2019, 381(16): 1524-1534. doi: 10.1056/NEJMoa1908973
[20]	KARATHANOS A, LIN Y, DANNENBERG L, et al. Routine glycoprotein Ⅱb/Ⅲa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis[J]. Can J Cardiol, 2019, 35(11): 1576-88. doi: 10.1016/j.cjca.2019.05.003
[21]	MCCARTNEY P J, ETEIBA H, MAZNYCZKA A M, et al. Effect of low-dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: a randomized clinical trial[J]. Jama, 2019, 321(1): 56-68. doi: 10.1001/jama.2018.19802
[22]	NICCOLI G, MONTONE R A, IBANEZ B, et al. Optimized treatment of ST-Elevation myocardial infarction[J]. Circulation research, 2019, 125(2): 245-58. doi: 10.1161/CIRCRESAHA.119.315344
[23]	BULLUCK H, SIRKER A, LOKE Y K, et al. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials[J]. Int J Cardiol, 2016, 202: 228-237. doi: 10.1016/j.ijcard.2015.09.005
[24]	YETGIN T, UITTERDIJK A, TE LINTEL HEKKERT M, et al. Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration[J]. JACC Cardiovasc Interv, 2015, 8(15): 1990-1999. doi: 10.1016/j.jcin.2015.08.033
[25]	NAZIR S A, MCCANN G P, GREENWOOD J P, et al. Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial[J]. Eur Heart J, 2016, 37(24): 1910-1919. doi: 10.1093/eurheartj/ehw136
[26]	AETESAM-UR-RAHMAN M, BROWN A J, JAWORSKI C, et al. Adenosine-induced coronary steal is observed in patients presenting with ST-segment-elevation myocardial infarction[J]. J Am Heart Assoc, 2021, 10(13): e019899 doi: 10.1161/JAHA.120.019899
[27]	SHENG X, DING S, GE H, et al. Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon[J]. Int J Cardiol, 2018, 265: 6-11. doi: 10.1016/j.ijcard.2018.04.119
[28]	KHAN K A, QAMAR N, SAGHIR T, et al. Comparison of intracoronary epinephrine and adenosine for no-reflow in normotensive patients with acute coronary syndrome (COAR Trial)[J]. Circ Cardiovasc Interv, 2022, 15(2): e011408. DOI: 10.1161/CIRCINTERVENTIONS.121.011408.
[29]	RIDKER P M, EVERETT B M, THUREN T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12): 1119-1131. doi: 10.1056/NEJMoa1707914
[30]	LIBERALE L, HOLY E W, AKHMEDOV A, et al. Interleukin-1β mediates arterial thrombus formation via NET-Associated tissue factor[J]. Journal of clinical medicine, 2019, 8(12): 2072. doi: 10.3390/jcm8122072
[31]	RIDKER P M, LIBBY P, MACFADYEN J G, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)[J]. European heart journal, 2018, 39(38): 3499-3507. doi: 10.1093/eurheartj/ehy310
[32]	CAO D, CHIARITO M, MEHRAN R. Treating inflammation prior to percutaneous coronary intervention: Does the heart care?[J]. Circ Cardiovasc Interv, 2020, 13(4): e009127. DOI: 10.1161/CIRCINTERVENTIONS.120.009127.
[33]	MORTON A C, ROTHMAN A M, GREENWOOD J P, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study[J]. Eur Heart J, 2015, 36(6): 377-384. doi: 10.1093/eurheartj/ehu272
[34]	KLEVELAND O, KUNSZT G, BRATLIE M, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial[J]. Eur Heart J, 2016, 37(30): 2406-2413. doi: 10.1093/eurheartj/ehw171
[35]	BROCH K, ANSTENSRUD A K, WOXHOLT S, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-Segment Elevation myocardial infarction[J]. J Am Coll Cardiol, 2021, 77(15): 1845-1855. doi: 10.1016/j.jacc.2021.02.049
[36]	DEFTEREOS S, GIANNOPOULOS G, ANGELIDIS C, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study[J]. Circulation, 2015, 132(15): 1395-1403. doi: 10.1161/CIRCULATIONAHA.115.017611
[37]	COLE J, HTUN N, LEW R, et al. Colchicine to prevent periprocedural myocardial injury in percutaneous coronary intervention: the COPE-PCI pilot trial[J]. Circ Cardiovasc Interv, 2021, 14(5): e009992. DOI: 10.1161/CIRCINTERVENTIONS.120.009992.
[38]	SHAH B, PILLINGER M, ZHONG H, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial[J]. Circ Cardiovasc Interv, 2020, 13(4): e008717. DOI: 10.1161/CIRCINTERVENTIONS.119.008717.
[39]	STONE G W, WEBB J, COX D A, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial[J]. Jama, 2005, 293(9): 1063-1072. doi: 10.1001/jama.293.9.1063
[40]	BAVRY A A, KUMBHANI D J, BHATT D L. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials[J]. Eur Heart J, 2008, 29(24): 2989-3001. doi: 10.1093/eurheartj/ehn421
[41]	JOLLY S S, CAIRNS J A, YUSUF S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy[J]. The New England journal of medicine, 2015, 372(15): 1389-1398. doi: 10.1056/NEJMoa1415098
[42]	JOLLY S S, JAMES S, DŽAVÍK V, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration[J]. Circulation, 2017, 135(2): 143-152. doi: 10.1161/CIRCULATIONAHA.116.025371
[43]	DESCH S, STIERMAIER T, DE WAHA S, et al. Thrombus aspiration in patients with ST-segment elevation myocardial infarction presenting late after symptom onset[J]. JACC Cardiovasc Interv, 2016, 9(2): 113-22. doi: 10.1016/j.jcin.2015.09.010
[44]	IBANEZ B, JAMES S, AGEWALL S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39(2): 119-177. doi: 10.1093/eurheartj/ehx393
[45]	FEISTRITZER H J, MEYER-SARAEI R, LOBER C, et al. Long-term outcome after thrombus aspiration in non-ST-elevation myocardial infarction: results from the TATORT-NSTEMI trial: thrombus aspiration in acute myocardial infarction[J]. Clin Res Cardiol, 2020, 109(10): 1223-1231. doi: 10.1007/s00392-020-01613-0